Case Reports in Medicine

Volume 2013 (2013), Article ID 561748, 3 pages

http://dx.doi.org/10.1155/2013/561748

Case Report

Autoimmune Hepatitis Triggered by Anti-TNF- Therapy

Satoshi Nakayama

Department of Gastroenterology, Mishuku Hospital, 5-33-12, Kamimeguro, Meguro-ku, Tokyo 153-0051, Japan

Received 21 June 2013; Accepted 9 August 2013

Academic Editor: Gerald S. Supinski

Copyright © 2013 Satoshi Nakayama. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Autoimmune hepatitis (AIH) is occasionally triggered by drug treatments. Recently, as biological agents are becoming widely used for autoimmune disorders, there have been a growing number of reports of the development of autoimmune processes related to these agents. A 52-year-old Japanese woman with psoriasis developed liver damage two months after initiation of anti-TNF-α therapy with adalimumab. Liver histological findings were compatible with AIH, and positive conversions of ANAs were detected. The patient was treated with prednisolone and had a good response. While some cases of AIH triggered by anti-TNF-α therapies have been reported, the pathogenesis remains unspecified. When elevation of liver enzymes is observed with high IgG levels and seropositivity of ANA during the course of anti-TNF-α therapy, liver biopsy findings may be essential and important to make definitive diagnosis of AIH.

1. Introduction

Approximately 9% of the cases of autoimmune hepatitis (AIH) are triggered by drugs [1]. Recently, as biological agents are becoming widely used for autoimmune disorders, there have been a growing number of reports of the development of autoimmune processes related to biological agents [2]. According to the registry data of the BIOGEAS project (a Spanish registry devoted to collecting data on the use of biological agents in adults with systemic autoimmune diseases), up to 2009, more than 800 cases developed autoimmune diseases associated with biological agents [2]. While drug-induced lupus, vasculitis, optical neuritis, interstitial lung disease, and inflammatory ocular disease accounted for more than 50% of new-onset autoimmune disorders, AIH also accounted for 2.0% [2].

2. Case Report

A 52-year-old Japanese woman with a 12-year history of psoriasis started anti-TNF-α therapy with adalimumab for exacerbation of skin lesions. The patient was not a habitual drinker and had no concomitant medications at the onset of the therapy. Hepatobiliary enzymes prior to therapy were within normal limits: asparate aminotransferase (AST) 20 U/L (normal value 8–38), alanine aminotransferase (ALT) 24 U/L (normal 4–44), and γ-glutamyl transferase (GGT) 43 U/L (normal 16–70). Hepatitis B surface antigen and anti-hepatitis C virus antibody were negative. Antinuclear antibodies (ANAs) measured using ELISA were also negative, 9.7 index (cutoff < 20).

Two months later, after six doses of adalimumab, she developed malaise with liver damage that continued after the discontinuation of adalimumab. A blood test three months after discontinuation showed the following: AST 240 U/L, ALT 224 U/L, alkaline phosphatase 723 U/L (normal 104–338) and GGT 228 U/L. Whilst serological tests for hepatitis A, B, and C viruses, Epstein-Barr virus, and cytomegalovirus were all negative, her serum immunoglobulin G levels were elevated (1969 mg/dL; normal 870–1700) and homogeneous and speckled-type ANAs were both present at titers of 1 : 160. Anti-smooth muscle antibody, anti-mitochondrial antibody, and anti-DNA antibody were negative. A percutaneous liver biopsy four months after discontinuation of adalimumab showed marked portal lymphoplasmacytic inflammation with periportal interface hepatitis and scattered lobular necroinflammatory changes (Figure 1). Accordingly, we diagnosed the patient as AIH and this was confirmed using simplified international diagnostic criteria (score 8 points; definite AIH ≥ 7) [3]. The patient was treated with 30 mg of prednisolone per day (0.5 mg/kg/day: standard initial therapy regimen for AIH in Japan) for 2 weeks with the reduction of the dose by 5 mg every 2 weeks, and the maintenance dose was set at 5 mg per day. Two months later, her hepatobiliary enzymes returned to normal. While the patient is still under the maintenance therapy, the relapse of AIH has not been observed.

Figure 1: Liver biopsy. Marked portal lymphoplasmacytic inflammation with periportal interface hepatitis and scattered lobular necroinflammatory changes may be seen. (hematoxylin and eosin; ×100).

3. Discussion

Some 20 cases of AIH triggered by anti-TNF-α therapy have been reported to date [3]. We have summarized the seven psoriatic cases with anti-TNF-α induced AIH, among which two patients were treated with adalimumab (Table 1) [4–8]. The median time and the number of doses of anti-TNF-α drugs to the onset of liver damage were 2 months and 3 times, respectively. All cases discontinued anti-TNF-α therapy after the onset of liver damage and six were treated with corticosteroid, with or without azathioprine. All cases had good responses to the therapies and prognosis; the liver damage was resolved within approximately 3 months in five cases. The same tendency was also seen in the cases other than the psoriasis reported previously [3].

Table 1: Reported cases of psoriasis with AIH triggered by anti-TNF-α therapy.

No.
Sex
Age (years)
Anti-TNF-α
Time to liver damage

Number of doses
Expressed autoantibodies
Treatment
Time to the resolution of liver damage

1 [4]
Female
53
Infliximab
26 weeks

6
ANA

Anti-ds DNA

ASMA
Fluocortolone
12 weeks

2 [5]
Female
22
Infliximab
6 weeks

2
ANA
Prednisone

Azathioprine
NA

3 [6]
Male
37
Infliximab
6 weeks

3
ANA

Anti-ds DNA

ASMA
Cessation only
2 months

4 [7]
Male
51
Infliximab
One month

3
ANA

Anti-ds DNA

AMA

Anti-cardiolipin antibodies
Azathioprine

Corticosteroids

Ursodeoxycholic acid
NA

5 [8]
Female
36
Adalimumab
3 months

6
ANA

Anti-ds DNA
Prednisone

Azathioprine
2 months

6 [8]
Female
47
Infliximab
10 weeks

3
ANA

ASMA
Prednisolone
3 months

7 (our case)
Female
52
Adalimumab
2 months

6
ANA
Prednisolone
2 months

ANA: anti-nuclear antibody, Anti-ds DNA: anti-double stranded DNA antibody, ASMA: anti-smooth muscle antibody, AMA: anti-mitochondrial antibody, PBC: primary biliary cirrhosis, and NA: not available.

One report suggested that it is sometimes a challenge to distinguish drug-induced AIH from de novo AIH or drug-induced liver injury because the clinical, biochemical, serological, and histological patterns may be similar in all these groups [9]. Furthermore, patients treated with biological agents may have various forms of simultaneous autoimmune disease and ANAs before treatment [9]. Certain data also suggested that 3% of AIH cases had psoriasis as a concurrent autoimmune disease [10].

Our patient could be diagnosed with AIH by positive conversion of ANAs after anti-TNF-α therapy and liver histological findings. In particular, liver biopsy findings must have been important to make definitive diagnosis of AIH.

The pathogenesis of AIH triggered by anti-TNF-α therapy remains unspecified [4]. TNF-α itself is suspected of contributing to the development of AIH [11], and an AIH case treated with anti-TNF-α inhibitor has also been reported [12]. In a certain case, AIH did not relapse after switching to another anti-TNF-α drug [13]. Perhaps, like other drugs, reactive metabolites of the anti-TNF-α drugs, which can be recognized by the immune system as neoantigens, may be one of the causes of AIH [1].

Occasionally, some patients may develop AIH after starting anti-TNF-α therapy for autoimmune disorders. Perhaps, most of them will develop AIH few months after initiation of the treatment and this will be resolved by intensive immunosuppressive therapy. Therefore, routine liver function test may be recommended during the course of anti-TNF-α therapy. When elevation of liver enzymes are observed with high IgG levels and seropotivity of ANA, liver biopsy findings may be essential and important to make definitive diagnosis of AIH.

References

E. Björnsson, J. Talwalkar, S. Treeprasertsuk et al., “Drug-induced autoimmune hepatitis: clinical characteristics and prognosis,” Hepatology, vol. 51, no. 6, pp. 2040–2048, 2010.

M. Ramos-Casals, R.-P. Roberto-Perez-Alvarez, C. Diaz-Lagares, M.-J. Cuadrado, and M. A. Khamashta, “Autoimmune diseases induced by biological agents: a double-edged sword?” Autoimmunity Reviews, vol. 9, no. 3, pp. 188–193, 2010.

A. Grasland, R. Sterpu, S. Boussoukaya, and I. Mahe, “Autoimmune hepatitis induced by adalimumab with successful switch to abatacept,” European Journal of Clinical Pharmacology, pp. 1–4, 2011.

V. Germano, A. P. Diamanti, G. Baccano et al., “Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis,” Annals of the Rheumatic Diseases, vol. 64, no. 10, pp. 1519–1520, 2005.

D. A. Fairhurst and R. Sheehan-Dare, “Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis,” Clinical and Experimental Dermatology, vol. 34, no. 3, pp. 421–422, 2009.

C. Goujon, K. Dahel, F. Bérard, I. Guillot, N. Gunera-Saad, and J.-F. Nicolas, “Autoimmune hepatitis in two psoriasis patients treated with inflixmab,” Journal of the American Academy of Dermatology, vol. 63, no. 2, pp. e43–e44, 2010.

T. Adar, M. Mizrahi, O. Pappo, A. Scheiman-Elazary, and O. Shibolet, “Adalimumab-induced autoimmune hepatitis,” Journal of Clinical Gastroenterology, vol. 44, no. 1, pp. e20–e22, 2010.

L. J. Dang, J. S. Lubel, S. Gunatheesan, P. Hosking, and J. Su, “Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis,” Australasian Journal of Dermatology, 2013.

C. Efe, “Drug induced autoimmune hepatitis and TNF-α blocking agents: is there a real relationship?” Autoimmunity Reviews, vol. 12, pp. 337–339, 2013.

C. Efe, S. Wahlin, E. Ozaslan et al., “Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases,” European Journal of Gastroenterology and Hepatology, vol. 24, no. 5, pp. 531–534, 2012.

S. Iwamoto, M. Kido, N. Aoki et al., “TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression,” Clinical Immunology, vol. 146, pp. 15–25, 2013.

C. Weiler-Normann, C. Wiegard, C. Schramm, and A. W. Lohse, “A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-α blockade,” American Journal of Gastroenterology, vol. 104, no. 11, pp. 2877–2878, 2009.

D. A. Goldfeld, E. C. Verna, J. Lefkowitch, and A. Swaminath, “Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn's disease: the index case,” Digestive Diseases and Sciences, vol. 56, no. 11, pp. 3386–3388, 2011.